The aim of the study was to investigate the prognostic role of extranodal extension (ENE) of lymph node metastasis in adenocarcinoma of the pancreas (PDAC) and papilla [cancer of the papilla of Vater (CPV)]. A PubMed and SCOPUS search from database inception until 5 January 2015 without language restrictions was conducted. Eligible were prospective studies reporting data on prognostic parameters in individuals with PDAC and/or CPV, comparing participants with the presence of ENE (ENE +) with those with intranodal extension (ENE). Data were summarized using risk ratios for number of deaths/recurrences and hazard ratios for time-dependent risk related to ENE+, adjusted for potential confounders. ENE was found to be very common in these tumors (up to about 60% in both N1-PDAC and CPV), leading to a significant increased risk for all-cause mortality [risk ratio= 1.20; 95% confidence interval (CI): 1.06'1.35, P=0.003, I2=44%; hazard ratio=1.415, 95% CI: 1.215'1.650, P <0.0001, I2= 0%] and recurrence of disease (risk ratio =1.20, 95% CI: 1.03'1.40, P=0.02, I2=0%). On the basis of our results, in PDAC and CPV, ENE should be considered mandatorily from the gross sampling and pathology report to the oncologic staging and therapeutic approach. © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Luchini, C., Veronese, N., Pea, A., Sergi, G., Manzato, E., Nottegar, A., et al. (2016). Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: A systematic review and meta-analysis of its prognostic significance. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 28(2), 205-209 [10.1097/MEG.0000000000000520].
Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: A systematic review and meta-analysis of its prognostic significance
Veronese, N.;
2016-01-01
Abstract
The aim of the study was to investigate the prognostic role of extranodal extension (ENE) of lymph node metastasis in adenocarcinoma of the pancreas (PDAC) and papilla [cancer of the papilla of Vater (CPV)]. A PubMed and SCOPUS search from database inception until 5 January 2015 without language restrictions was conducted. Eligible were prospective studies reporting data on prognostic parameters in individuals with PDAC and/or CPV, comparing participants with the presence of ENE (ENE +) with those with intranodal extension (ENE). Data were summarized using risk ratios for number of deaths/recurrences and hazard ratios for time-dependent risk related to ENE+, adjusted for potential confounders. ENE was found to be very common in these tumors (up to about 60% in both N1-PDAC and CPV), leading to a significant increased risk for all-cause mortality [risk ratio= 1.20; 95% confidence interval (CI): 1.06'1.35, P=0.003, I2=44%; hazard ratio=1.415, 95% CI: 1.215'1.650, P <0.0001, I2= 0%] and recurrence of disease (risk ratio =1.20, 95% CI: 1.03'1.40, P=0.02, I2=0%). On the basis of our results, in PDAC and CPV, ENE should be considered mandatorily from the gross sampling and pathology report to the oncologic staging and therapeutic approach. © 2016 Wolters Kluwer Health, Inc. All rights reserved.File | Dimensione | Formato | |
---|---|---|---|
meg.0000000000000520.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
434.95 kB
Formato
Adobe PDF
|
434.95 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.